New combo therapy targets deadly stomach cancer fluid buildup
NCT ID NCT06759064
First seen Nov 19, 2025 · Last updated May 20, 2026 · Updated 20 times
Summary
This early-phase study tests whether injecting an immunotherapy drug plus a bone-strengthening drug directly into the belly can safely reduce fluid buildup caused by stomach cancer. About 24 adults with confirmed stomach cancer and malignant ascites will receive the treatment. The goal is to find the best dose and see if it shrinks the fluid and tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASCITES, MALIGNANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shandong, 250012, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.